Cronos Group (NASDAQ:CRON) posted its earnings results on Tuesday. The company reported ($0.01) earnings per share (EPS) for the quarter, Morningstar.com reports. Cronos Group had a return on equity of 3.41% and a net margin of 35.12%. The firm had revenue of $2.33 million for the quarter.
CRON stock opened at $6.04 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.85 and a current ratio of 3.39. Cronos Group has a 52-week low of $6.02 and a 52-week high of $6.34. The stock has a market cap of $1.10 billion and a PE ratio of 604.00.
Several equities research analysts have recently issued reports on CRON shares. Canaccord Genuity lowered shares of Cronos Group from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. GMP Securities raised shares of Cronos Group from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. Finally, Beacon Securities reissued a “buy” rating on shares of Cronos Group in a research note on Friday, May 4th.
About Cronos Group
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.